Opinion|Videos|February 29, 2024
Prospective Trial Data on MRD Testing in Early-Stage CRC
An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Is Vitamin C an Epigenetic Interception Strategy in Pre-Leukemic Disease?
3
AI Foundation Models & Molecular Biomarkers in Breast Cancer
4
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
5